34 active not recruiting. 34 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Active not recruiting 34 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis Icotrokinra, Placebo - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 896 | 2025-10-01 | 2026-11-03 |
| A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab Risankizumab, Vedolizumab - Ulcerative Colitis | Phase 3 | Active not recruiting | AbbVie | 573 | 2025-06-17 | 2026-08-04 |
| Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine S. Flexneri-S. Sonnei bivalent conjugate vaccine, Placebo - Dysentery, Dysentery, Shigella | Phase 3 | Active not recruiting | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 8000 | 2025-05-12 | 2026-04-01 |
| Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Upadacitinib - Crohn's Disease | Phase 3 | Active not recruiting | AbbVie | 111 | 2024-08-08 | 2026-10-16 |
| Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients Guselkumab - Crohn's Disease | Phase 3 | Active not recruiting | Janssen-Cilag Ltd. | 120 | 2024-04-17 | 2026-11-03 |
| A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab Subcutaneous, Guselkumab Intravenous - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 112 | 2024-01-19 | 2026-11-03 |
| A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. Risankizumab SC, Placebo for risankizumab - Crohn's Disease | Phase 3 | Active not recruiting | AbbVie | 289 | 2023-11-15 | 2025-09-09 |
| Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. Upadacitinib - Ulcerative Colitis | Phase 3 | Active not recruiting | AbbVie | 122 | 2023-11-06 | 2026-05-14 |
| A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) IV Tulisokibart, IV Placebo, SC Tulisokibart - Ulcerative Colitis | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 1109 | 2023-10-25 | 2026-09-28 |
| Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis encapsulated faecal microbiota filtrate, encapsulated faecal microbiota, Placebo - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 3 | Active not recruiting | Andreas Stallmach | 84 | 2023-01-31 | 2026-08-10 |
| ABTECT - Maintenance ABX464, Placebo - Ulcerative Colitis | Phase 3 | Active not recruiting | Abivax S.A. | 1116 | 2023-01-16 | 2026-07-07 |
| Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Tezepelumab, Placebo - Eosinophilic Esophagitis | Phase 3 | Active not recruiting | AstraZeneca | 368 | 2022-11-10 | 2026-10-30 |
| A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 418 | 2022-09-13 | 2026-11-04 |
| A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3 - Crohn Disease | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 350 | 2022-01-19 | 2026-09-25 |
| A Long-term Extension Study of Ustekinumab in Pediatric Participants Ustekinumab - Crohn Disease, Colitis, Ulcerative | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 159 | 2021-10-18 | 2026-11-03 |
| Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis tofacitinib - Ulcerative Colitis | Phase 3 | Active not recruiting | Pfizer | 118 | 2021-08-12 | 2026-08-03 |
| A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease Vedolizumab - Ulcerative Colitis, Crohn's Disease | Phase 3 | Active not recruiting | Takeda | 56 | 2021-06-04 | 2026-06-15 |
| Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE Budesonide - Eosinophilic Esophagitis | Phase 3 | Active not recruiting | Dr. Falk Pharma GmbH | 308 | 2021-05-21 | 2026-08-28 |
| Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) Risankizumab, Ustekinumab - Crohn's Disease (CD) | Phase 3 | Active not recruiting | AbbVie | 527 | 2020-09-30 | 2026-04-13 |
| A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease Mirikizumab - Crohn's Disease | Phase 3 | Active not recruiting | Eli Lilly and Company | 996 | 2020-06-22 | 2026-08-11 |
Showing 20 of 34. Sign in to see all of them.
Colitis, Ulcerative (18) · Crohn Disease (11) · Inflammatory Bowel Diseases (4) · Enterocolitis, Necrotizing (2) · Eosinophilic Esophagitis (2) · Arthritis, Psoriatic (1) · Digestive System Diseases (1) · Dysentery (1) · Dysentery, Bacillary (1) · Dyspepsia (1) · Esophagitis (1) · Gastroesophageal Reflux (1) · Gastroparesis (1) · Heartburn (1) · Nausea (1)
Gastrointestinal Diseases (34) · Digestive System Diseases (33) · Intestinal Diseases (31) · Inflammatory Bowel Diseases (23) · Colitis (18) · Colonic Diseases (18) · Esophageal Diseases (3) · Enterocolitis (2) · Eosinophilia (2) · Esophagitis (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2)
risankizumab (5) · guselkumab (4) · upadacitinib (4) · Ustekinumab (3) · Fecal Microbiota Transplantation (2) · mirikizumab (2) · vedolizumab (2) · ABX464 (1) · Budesonide (1) · Domperidone (1) · Infliximab (1) · etrasimod (1) · golimumab (1) · tezepelumab (1) · tofacitinib (1)
AbbVie (9) · Janssen Research & Development, LLC (8) · Eli Lilly and Company (2) · Pfizer (2) · Abivax S.A. (1) · Andreas Stallmach (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · Dr. Falk Pharma GmbH (1) · Infant Bacterial Therapeutics (1) · Janssen-Cilag Ltd. (1) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Nantes University Hospital (1)
United States (28) · France (26) · Poland (25) · Israel (24) · Spain (24) · Belgium (23) · Italy (23) · Canada (22) · Germany (22) · Japan (22) · United Kingdom (21) · Australia (20) · Czechia (20) · South Korea (20) · China (19)
Alfredo J Lucendo, MD, PhD (1) · Andreas Stallmach, Prof. (1) · Bruce Sands, MD, PhD (1) · Josef Neu, MD (1) · Lin Du (1) · Mehnaz Shafi (1)
PMID 40357993, PMID 41763462, PMID 11237120, PMID 12394384, PMID 17681163, PMID 27159210, PMID 28417994, PMID 31504429, PMID 32079889, PMID 32493442, PMID 34815288, PMID 35134323, PMID 35193638, PMID 35644155, PMID 36917429, PMID 37224198, PMID 37368103, PMID 37659673, PMID 37797293, PMID 38104569, PMID 38492903, PMID 38492904, PMID 38545091, PMID 38556499, PMID 38835235, PMID 38863178, PMID 38982567, PMID 39018531, PMID 39037800, PMID 39054592, PMID 39131711, PMID 39231444, PMID 39326583, PMID 39448057, PMID 39485390, PMID 39706209, PMID 39778975, PMID 39802486, PMID 39804294, PMID 39909280, PMID 40071779, PMID 40113101, PMID 40168091, PMID 40347957, PMID 40348496, PMID 40574492, PMID 40684778, PMID 40704669, PMID 40738276, PMID 40875187
2023 (14), 2017 (4), 2018 (2), 2019 (1), 2025 (1)